Caplin Point Laboratories Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-c6b09d46061c5f3197f7ac95.pdf

Key Takeaways


US Business: The B2C Transition

C.C. Paarthipan: "This margins which has come down is the one which makes me to go to the market actually starting from January, because there are some markets you understand you can actually manage. You can also create new versions in our business, but there are some markets which are monopolies and near place where you have to work with the system."

CSU & LATAM: The Direct-to-Last-Mile Bet

C.C. Paarthipan: "In a commodity world, there are only 3 ways to win. Be cheaper. Number 2, be faster. And number 3, be different. The first 2, I think they are temporary, and the third is more durable."

Facilities & Capex: Building for 2030

C.C. Paarthipan: "We don't try to grow on shaky ground... We always systematize before we scale."

Margins, Costs & Cash Flow


Inorganic Opportunities & Capital Allocation


Raw Material & External Risks

C.C. Paarthipan: "Having waited with us actually for so long, we're not telling you actually that, you know, we are not in a position to show you the sunshine. We will definitely show you. It's a question of time. That's what I'm telling. That time also is not very far. It's 2-3 years maximum."

Guidance & Commitments

CommitmentSpecificsTimeline
US revenue growth20% to 25% growth target for FY27 (Caplin Steriles)FY27
US margin recoveryQ3 and Q4 margins back on rails compared to last year's percentages, if not better (Caplin Steriles)Q3–Q4 FY27
PAT marginWell on target to yield 25–26% PATFY27
Effective tax rateAround 20% to 21%Full year FY27
Inventory normalizationInventory to come down to normal levels (120–150 days benchmark)By March
CSU revenue and profitabilityDouble revenue and profitabilityFY27
US new product launches10 productsNext financial year
COL2 facility completionCompletion with 6 injectable lines including ophthalmic and blow-fill sealAugust 2027
COL2 first revenue15–18 months from completion to revenue (site transfer, stability, filing, inspection)FY28–'29 and beyond
CRO capacityExpand from 72 to 120 beds; target 6–8 BE studies per monthEnd of FY27
Oncology API siteOperationalBefore end of next calendar year
First API DMF filingsFirst few DMFs from API siteWithin next year
Paperless factoryEntire digitization, video SOP, paperless factory completed3 months
Line 1 and Line 3 upgradesDowntime until December, then production resumesDecember
Mexico distribution acquisitionChairman's January visit expected to complete the acquisitionJanuary
Best performance"Sunshine" for shareholders; best performance starting2-3 years from now

Key Metrics

MetricQ2 FY27
Operating revenue₹1,240 cr, +18.2% YoY, equally distributed between US and LATAM
EBITDA margin38.7%
PBT margin38%
PAT margin27.2%
Effective tax rate~15%; full-year target 20–21%
Gross profit improvement+1.5% over previous quarter
Cash and cash equivalents~₹1,500 cr
Net worth₹3,963 cr
Cash flow from operations₹205 cr, vs ₹250 cr last year
Inventory increase~₹115 cr; 50% to be sold this year, ₹45 cr toward supply tender
Receivables increase~₹70 cr, from government tenders supplied in last 6 months
Capex spent (current year)>₹130 cr, mostly advance payments for lines
COL2 capex planned₹500–600 cr over next 12–18 months
Caplin One Labs (OSD) capex₹120–150 cr over next 12 months
CSL revenue contribution₹271 cr, +21% over previous year
US business H1 FY27 realization₹103 cr, exceeding full FY26 turnover of ₹92 cr
Caplin Steriles products launched in US40
CSU daily average sales$61,000, nearly doubled from $33,000 last year
CSU FY27 expectationRevenue and profitability to double
US new products planned (next financial year)10
Pre-filled syringe products2 exhibit batches completed, 12 under development
APIs scaled up5 (4 secondary source, 1 primary source)
CRO bed expansionFrom 72 to 120 beds by end of FY27; target 6–8 BE studies per month
COL2 facility completionExpected by August '27
Inventory days (benchmark)120–150 days
US business H1 EBITDA34.2%, up from 29.5% H1 last year
US business H1 PBT23.5%, up from 19.9% H1 last year
US business FY27 growth target20–25%
Exports from China~30% of goods